期刊文献+

宫颈癌患者HPV感染状况及外周血Th1/Th2细胞因子变化研究 被引量:22

HPV Infection Status,Changes of Th1 and Th2 in Peripheral Blood of Uterine Cerivical Cancer Patients
下载PDF
导出
摘要 目的探讨宫颈癌患者人乳头瘤病毒(HPV)感染状况及外周血Th1/Th2细胞因子变化,分析其在宫颈癌发生及发展中所起的可能机制,为宫颈癌的临床防治提供参考。方法选取80例宫颈癌患者为研究对象(宫颈癌组),选取同期门诊体检的健康女性80例为对照(对照组),采用荧光定量聚合酶链反应(FQ-PCR)检测宫颈HPV-DNA,应用酶联免疫吸附法检测Th1/Th2细胞因子水平,包括白细胞介素-2(IL-2)和干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)和白细胞介素-6(IL-6)。结果宫颈癌组70例检出HPV,感染率为87.50%,对照组5例检出HPV,感染率为6.25%,比较差异有统计学意义(P<0.05),宫颈癌组HPV分型60例高危型、10例低危型,分别占85.71%、14.29%,38例单一感染、32例多重感染,分别占54.29%、45.71%,对照组HPV分型0例高危型、5例低危型,分别占0.00%、100.00%,5例单一感染、0例多重感染,分别占100.00%、0.00%,两组HPV分型及感染类型比较差异有统计学意义(P<0.05);宫颈癌组外周血IL-2和IFN-γ、IL-4、IL-6水平分别为(43.08±8.56)pg/ml、(56.15±9.47)pg/ml、(28.55±6.39)pg/ml、(34.29±7.80)pg/ml,明显高于对照组(18.94±4.57)pg/ml、(28.28±7.78)pg/ml、(12.39±3.90)pg/ml、(16.62±3.49)pg/ml,比较差异有统计学意义(P<0.05);宫颈癌组HPV感染患者外周血IL-2和IFN-γ、IL-4、IL-6水平明显高于无HPV感染患者,比较差异有统计学意义(P<0.05);对照组HPV感染者外周血IL-2和IFN-γ、IL-4、IL-6水平明显高于无HPV感染者,比较差异有统计学意义(P<0.05)。结论宫颈癌患者存在HPV感染率增高及外周血Th1/Th2细胞因子紊乱,HPV感染可加重Th1/Th2细胞因子紊乱,HPV感染及外周血Th1/Th2细胞因子紊乱在宫颈癌的发生发展中可能起到了促进作用。 Objective To discuss the HPV infection status,changes of Th1 and Th2 in peripheral blood of uterine cerivical cancer patients,to analyze the possible mechanism of uterine cerivical cancer in its occurrence and development,it provides reference for the clinical prevention and treatment of cuterine cerivical cancer.Methods The 80 cases uterine cerivical cancer patients(uterine cerivical cancer group),according to the actual timing of tracheotomy,and 90 healthy women were included in the analysis(control group),fluorescence quantitative polymerase chain reaction(FQ-PCR)was used to detect cervical HPV-DNA,the levels of Th1/Th2 cytokines were detected by enzyme-linked immunosorbent assay,these include interleukin-2(IL-2)and interferon-γ(IFN-γ),interleukin-4(IL-4),and interleukin-6(IL-6).Results 70 cases of HPV infection of the uterine cerivical cancer group,the infection rate were 87.50%,5 cases of HPV infection of the control group,the infection rate were 6.25%,the difference was statistically significant(P<0.05);There were 60 cases of high-risk type(85.71%)and 10 cases of low-risk type(14.29%),38 cases of single infection(54.29%)and 32 cases of multiple infection(45.71%)with the uterine cerivical cancer group,there were 0 case of high-risk type(0.00%)and 5 cases of low-risk type(100.00%),5 cases of single infection(100.00%)and 0 case of multiple infection(0.00%)with the control group,the difference wasstatistically significant(P<0.05).IL-2 were(43.08±8.56)pg/ml,IFN-γwere(56.15±9.47)pg/ml,IL-4 were(28.55±6.39)pg/ml,IL-6 were(34.29±7.80)pg/ml of the uterine cerivical cancer group,IL-2 were(18.94±4.57)pg/mlpg/ml,IFN-γwere(28.28±7.78)pg/ml,IL-4 were(12.39±3.90)pg/ml,IL-6 were(16.62±3.49)pg/ml of the control group,the difference wasstatistically significant(P<0.05).IL-2,IFN-γ,IL-4,IL-6 of HPV infection patients higher than non HPV infection patients higher the uterine cerivical cancer group,IL-2,IFN-γ,IL-4,IL-6 of HPV infection patients higher than non HPV infection patients higher the control group,the difference wasstatistically significant(P<0.05).Conclusion HPV infection higher,inordinate of Th1 and Th2 in peripheral blood of uterine cerivical cancer patients,HPV infection and Th1/Th2 cytokine disorder in peripheral blood may play a role in promoting the development of cervical cancer.
作者 姜爱华 孙俊红 张芳芳 李自平 JIANG Aihua;SUN Junhong;ZHANG Fangfang(Puyang People's Hospital,Puyang,457000)
出处 《实用癌症杂志》 2021年第4期555-558,共4页 The Practical Journal of Cancer
关键词 宫颈癌 人乳头瘤病毒 TH1/TH2 细胞因子 Uterine cerivical cancer HPV Th1/Th2 Cytokines
  • 相关文献

参考文献5

二级参考文献61

  • 1Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment [ J ]. Science, 2015,348 ( 6230 ) : 74 - 80.
  • 2Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy[ J ]. Science, 2013,342 ( 6165 ) : 1432 - 1433.
  • 3Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer[ J ]. Nat Rev Clin Onco1,2014,11 ( 1 ) :24 - 37.
  • 4Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med,2015,21 ( 1 ) :24 - 33.
  • 5Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, et al. Or- chestrating immune check-point blockade for cancer im- munotherapy in combinations [ J ]. Curr Opin Immunol, 2014,27:89 - 97.
  • 6Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD- L1 to reactivate the host immune response against cancer [ J ]. Br J Cancer,2013,108 (8) : 1560 - 1565.
  • 7Rosenberg SA, Restifo NP. Adoptive cell transfer as per- sonalized immunotherapy for human cancer [ J ]. Science, 2015,348 (6230) :62 -68.
  • 8Gross G, Waks T, Eshhar Z. Expression of immunoglobu- lin-T-cell receptor chimeric molecules as functional recep-tors with antibody-type specificity[J]. Proc Nat1 Acad Sci U S A, 1989,86 (24) : 10024 - 10028.
  • 9Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young aduhs: a phase 1 dose-escalation trial [ J ]. Lancet, 2015, 385 (9967) :517 - 528.
  • 10Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making [ J ]. Blood Rev, 2015. Epub ahead of print.

共引文献79

同被引文献252

引证文献22

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部